IL265199B2 - Metabolite biomarkers for diseases related to the activation of the communication system - Google Patents

Metabolite biomarkers for diseases related to the activation of the communication system

Info

Publication number
IL265199B2
IL265199B2 IL265199A IL26519919A IL265199B2 IL 265199 B2 IL265199 B2 IL 265199B2 IL 265199 A IL265199 A IL 265199A IL 26519919 A IL26519919 A IL 26519919A IL 265199 B2 IL265199 B2 IL 265199B2
Authority
IL
Israel
Prior art keywords
metabolite
hae
subject
level
biomarker
Prior art date
Application number
IL265199A
Other languages
English (en)
Hebrew (he)
Other versions
IL265199B1 (en
IL265199A (en
Original Assignee
Dyax Corp
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp, Takeda Pharmaceuticals Co filed Critical Dyax Corp
Publication of IL265199A publication Critical patent/IL265199A/en
Publication of IL265199B1 publication Critical patent/IL265199B1/en
Publication of IL265199B2 publication Critical patent/IL265199B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Diabetes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL265199A 2016-09-16 2017-09-15 Metabolite biomarkers for diseases related to the activation of the communication system IL265199B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395770P 2016-09-16 2016-09-16
US201762518367P 2017-06-12 2017-06-12
PCT/US2017/051755 WO2018053247A1 (en) 2016-09-16 2017-09-15 Metabolite biomarkers for diseases associated with the contact activation system

Publications (3)

Publication Number Publication Date
IL265199A IL265199A (en) 2019-05-30
IL265199B1 IL265199B1 (en) 2024-09-01
IL265199B2 true IL265199B2 (en) 2025-01-01

Family

ID=59974882

Family Applications (2)

Application Number Title Priority Date Filing Date
IL265199A IL265199B2 (en) 2016-09-16 2017-09-15 Metabolite biomarkers for diseases related to the activation of the communication system
IL314752A IL314752A (en) 2016-09-16 2017-09-15 Metabolite biomarkers for diseases associated with the contact activation system

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL314752A IL314752A (en) 2016-09-16 2017-09-15 Metabolite biomarkers for diseases associated with the contact activation system

Country Status (12)

Country Link
US (3) US11340237B2 (enExample)
EP (1) EP3513197A1 (enExample)
JP (4) JP7225090B2 (enExample)
KR (3) KR20250030022A (enExample)
CN (2) CN117169508A (enExample)
AU (1) AU2017325986B2 (enExample)
BR (1) BR112019005167A2 (enExample)
CA (1) CA3037157A1 (enExample)
CO (1) CO2019002607A2 (enExample)
IL (2) IL265199B2 (enExample)
MX (2) MX2019002918A (enExample)
WO (1) WO2018053247A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011204349C1 (en) 2010-01-06 2017-02-16 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
ES2856076T3 (es) * 2014-01-21 2021-09-27 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática y usos de las mismas en el tratamiento de angioedema hereditario
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
MX2019002932A (es) 2016-09-16 2019-07-15 Dyax Corp Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto.
EP3513197A1 (en) 2016-09-16 2019-07-24 Dyax Corp. Metabolite biomarkers for diseases associated with the contact activation system
EP3521828A1 (en) * 2018-01-31 2019-08-07 Centogene AG Method for the diagnosis of hereditary angioedema
CA3144694A1 (en) 2019-07-25 2021-01-28 Jose A. Horcajadas Identification of viable human embryos
CN110514772A (zh) * 2019-08-09 2019-11-29 中国医学科学院基础医学研究所 透明肾细胞癌代谢标志物在肾细胞癌早期筛查和诊断产品中的应用
EP4126219A2 (en) * 2020-04-04 2023-02-08 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
CN113495137A (zh) * 2021-06-29 2021-10-12 江苏省中医院 两种代谢标志物单独或联合在制备诊断克罗恩病的试剂盒中的应用
CN117310059B (zh) * 2023-11-30 2024-02-02 中国人民解放军总医院 用于早期诊断或监测克罗恩病的血浆代谢标志物组合及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100105076A1 (en) * 2007-03-20 2010-04-29 Polyintell Analysis kit comprising at least two molecularly imprinted polymers and at least one marker, and method of analysis using same
WO2011061304A1 (en) * 2009-11-20 2011-05-26 Pharnext New diagnostic tools for charcot-marie-tooth disease
US20140086825A1 (en) * 2012-09-24 2014-03-27 William J. McFaul Methods and kits for assessing, modulating and treating substances affecting bodily processes

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739355B1 (en) 1994-01-11 2004-09-08 Dyax Corporation Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US7064107B2 (en) 2002-06-07 2006-06-20 Dyax Corp. Prevention and reduction of blood loss
EP1711828A2 (en) 2004-01-28 2006-10-18 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2)
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
ITMI20041963A1 (it) * 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
US20070218519A1 (en) 2005-10-11 2007-09-20 Tethys Bioscience, Inc. Diabetes-associated markers and methods of use thereof
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US7625944B2 (en) * 2006-07-31 2009-12-01 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
US20080031816A1 (en) 2006-08-03 2008-02-07 Charles Keller Methods and compositions for identifying biomarkers
WO2008046517A1 (en) 2006-10-16 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Ctgf as a biomarker, therapeutic and diagnostic target
WO2008046510A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Fn1 as a biomarker, therapeutic and diagnostic target
WO2008046528A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Npr3 as a biomarker, therapeutic and diagnostic target
WO2008046512A1 (en) 2006-10-16 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Prss23 as a biomarker, therapeutic and diagnostic target
WO2008046508A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Tgfb2 as a biomarker, therapeutic and diagnostic target
US20100081136A1 (en) 2006-10-16 2010-04-01 Stefan Golz Crtac as a biomarker, therapeutic and diagnostic target
US8088584B2 (en) 2006-10-16 2012-01-03 Bayer Schering Pharma Aktiengesellschaft LTBP2 as a biomarker and diagnostic target
JP5564491B2 (ja) * 2008-04-29 2014-07-30 サイケメディクス コーポレイション 固相多分析物アッセイ法
WO2010045180A1 (en) * 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
WO2011019072A1 (ja) * 2009-08-12 2011-02-17 ヒューマン・メタボローム・テクノロジーズ株式会社 うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体
US20110098993A1 (en) 2009-10-27 2011-04-28 Anaxomics Biotech Sl. Methods and systems for identifying molecules or processes of biological interest by using knowledge discovery in biological data
WO2011053831A1 (en) 2009-10-30 2011-05-05 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
AU2011204349C1 (en) 2010-01-06 2017-02-16 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
CA2793735A1 (en) 2010-03-23 2011-09-29 M. Daniel Raftery Early detection of recurrent breast cancer using metabolite profiling
US20120040383A1 (en) 2010-08-12 2012-02-16 Wei Jia Methods and Kits Relating To Metabolite Biomarkers For Colorectal Cancer
WO2012094587A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
JP5986440B2 (ja) 2012-07-05 2016-09-06 国立医薬品食品衛生研究所長 アルツハイマー病の発症を予測する方法
US10220089B2 (en) 2012-08-29 2019-03-05 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
SMT201900204T1 (it) 2013-01-20 2019-05-10 Dyax Corp Valutazione, saggi e trattamento di disturbi mediati da pkal
IL273688B2 (en) 2013-01-20 2024-12-01 Dyax Corp Evaluation and treatment of bradykinin-mediated disorders
JP2016514141A (ja) 2013-03-14 2016-05-19 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド Ｂ２−ブラジキニン受容体媒介の血管浮腫の治療方法
SG11201506875YA (en) * 2013-03-15 2015-09-29 Intrexon Corp Boron-containing diacylhydrazines
KR20250066486A (ko) * 2013-10-21 2025-05-13 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
EP2884282A1 (en) * 2013-12-13 2015-06-17 CONARIS research institute AG Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency
AU2015243857A1 (en) 2014-04-08 2016-10-20 Metabolon, Inc. Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
TWI614501B (zh) 2014-09-22 2018-02-11 National Health Research Institutes ５-甲氧基色胺酸作為發炎疾病診斷試劑之用途
AU2016243160B2 (en) * 2015-03-30 2022-02-24 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
BR112018002742B1 (pt) 2015-08-13 2023-05-16 Takeda Pharmaceutical Company Limited Tubo de coleta de sangue evacuado, método para a avaliação do nível endógeno de ativação do sistema de contato em um sujeito, método para a avaliação do nível de um fármaco visando o sistema de contato em um sujeito e método para a avaliação da imunogenicidade de um fármaco visando o sistema de contato
JP6570472B2 (ja) 2016-03-30 2019-09-04 株式会社マンダム 毛髪の損傷の評価方法
EP3513197A1 (en) 2016-09-16 2019-07-24 Dyax Corp. Metabolite biomarkers for diseases associated with the contact activation system
MX2019002932A (es) 2016-09-16 2019-07-15 Dyax Corp Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto.
BR112019005172A2 (pt) 2016-09-16 2019-07-02 Dyax Corp. método e kit para analisar uma amostra

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100105076A1 (en) * 2007-03-20 2010-04-29 Polyintell Analysis kit comprising at least two molecularly imprinted polymers and at least one marker, and method of analysis using same
WO2011061304A1 (en) * 2009-11-20 2011-05-26 Pharnext New diagnostic tools for charcot-marie-tooth disease
US20140086825A1 (en) * 2012-09-24 2014-03-27 William J. McFaul Methods and kits for assessing, modulating and treating substances affecting bodily processes

Also Published As

Publication number Publication date
JP7225090B2 (ja) 2023-02-20
JP2023058612A (ja) 2023-04-25
JP2025124816A (ja) 2025-08-26
US20190361036A1 (en) 2019-11-28
CN109716137B (zh) 2023-07-21
US20220365101A1 (en) 2022-11-17
AU2017325986B2 (en) 2023-12-14
CA3037157A1 (en) 2018-03-22
KR20190053914A (ko) 2019-05-20
BR112019005167A2 (pt) 2019-07-02
MX2019002918A (es) 2019-07-18
AU2024200561A1 (en) 2024-02-15
JP7692508B2 (ja) 2025-06-13
NZ751481A (en) 2024-02-23
WO2018053247A1 (en) 2018-03-22
IL314752A (en) 2024-10-01
JP2024059990A (ja) 2024-05-01
MX2024004195A (es) 2024-04-23
KR102775437B1 (ko) 2025-03-05
KR20220154245A (ko) 2022-11-21
JP2019534446A (ja) 2019-11-28
KR102464380B1 (ko) 2022-11-07
IL265199B1 (en) 2024-09-01
US11340237B2 (en) 2022-05-24
JP7451791B2 (ja) 2024-03-18
IL265199A (en) 2019-05-30
AU2017325986A1 (en) 2019-04-04
KR20250030022A (ko) 2025-03-05
CO2019002607A2 (es) 2019-03-29
CN109716137A (zh) 2019-05-03
US20250199014A1 (en) 2025-06-19
CN117169508A (zh) 2023-12-05
EP3513197A1 (en) 2019-07-24
US12188948B2 (en) 2025-01-07

Similar Documents

Publication Publication Date Title
US12188948B2 (en) Metabolite biomarkers for diseases associated with the contact activation system
US20240142468A1 (en) Protein biomarkers for diseases associated with the contact activation system
AU2024200561B2 (en) Metabolite biomarkers for diseases associated with the contact activation system
HK40102782A (zh) 用於与接触活化系统相关的疾病的代谢产物生物标记
NZ792393A (en) Metabolite biomarkers for diseases associated with the contact activation system
WO2024003617A2 (en) Protein biomarkers for lanadelumab treatment
EA045712B1 (ru) Белковые биомаркеры заболеваний, ассоциированных с контактной системой активации